Value of FLT PET/CT in Radium-223 Therapy of mCRPC Patients
Not Applicable
Terminated
- Conditions
- Metastatic Prostate Carcinoma
- Registration Number
- NCT03011749
- Lead Sponsor
- Rigshospitalet, Denmark
- Brief Summary
The aim of the study is to investigate whether positron emission tomography (PET) using the tracer 18F-Fluorothymidine (FLT) can provide information on proliferative activity in bone marrow of patients receiving Radium 223 therapy and potentially be a predictive marker of hematological toxicity
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- Male
- Target Recruitment
- 6
Inclusion Criteria
- Metastatic castration resistant prostate cancer
- Eligible for Radium-223 therapy
- Informed consent
Exclusion Criteria
- Inability to understand study protocol
- Extensive metastatic involvement of the axial skeleton ("superscan" on bone scintigraphy)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Uptake of FLT in hematological bone marrow 3 months
- Secondary Outcome Measures
Name Time Method Occurrence of hematological toxicity 12 months
Trial Locations
- Locations (1)
Rigshospitalet
🇩🇰Copenhagen, Denmark
Rigshospitalet🇩🇰Copenhagen, Denmark